Eisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire women to listen, advocate and put their health and the health of other women first.
WOODCLIFF LAKE, N.J., March 31, 2021 /PRNewswire/ -- Eisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire women to listen, advocate and put their health and the health of other women first. The initiative is in partnership with SHARE Cancer Support (SHARE), Facing Our Risk of Cancer Empowered (FORCE) and Black Health Matters to raise awareness of one of the most common yet under-recognized women's cancers. Uterine cancer is one of the few cancers where both diagnoses and death rates are on the rise, and endometrial cancer accounts for 90% of all uterine cancers. The Spot Her initiative aims to embrace the power of every woman's voice to take a stand on this important women's health issue by providing support through education, resources and strength through community. "Despite the large number of women affected, discussion around endometrial cancer lags far behind other women's cancers; therefore, it's critical that women of all ages learn about this disease. Spot Her empowers us to be outspoken about this disease for the women in our lives – our mothers, our aunts, our sisters, our friends, ourselves," said Sue Friedman, Executive Director at FORCE. "Oftentimes, these symptoms can be easily overlooked, mistaken for other conditions, or dismissed. It's important to overcome the stigma still associated with openly discussing women's 'below the belt' health, because talking about these symptoms with each other and a doctor could help more women spot the cancer early, when it's more treatable." Endometrial cancer may occur more commonly in post-menopausal women, but diagnoses are on the rise among younger women between the ages of 20 to 49, when fertility may be an important concern. Endometrial cancer can also affect women across generations, who may be more at risk for the disease due to genetic factors and other health conditions. Some common signs of endometrial cancer may include abnormal bleeding, spotting, or brownish discharge after menopause, as well as irregular or heavy bleeding in women before menopause, and pelvic pain or pressure. "As a human health care company fueled by our compassion for patients, Eisai is committed to making a meaningful difference by addressing the unmet needs and disparities within the endometrial cancer community," said Teresa Cronin, Senior Director of Corporate Advocacy at Eisai. "Through this initiative with SHARE, FORCE and Black Health Matters, we hope to empower women to 'Spot Her' by listening, identifying and speaking up about what could be endometrial cancer." "We know that when women come together to rally around a cause, change happens," said Nefa-Tari Moore, Uterine/Endometrial Program and Outreach Coordinator with SHARE. "Together we hope to inspire others to join us as we raise our voices around this serious cancer and give endometrial cancer the attention it deserves." "Due to the inequality of health outcomes for Black women, it is especially important for them to be able to identify symptoms and seek help. Only 53% of Black women with endometrial cancer receive an early diagnosis, so it is important that they are aware of the symptoms," said Roslyn Daniels, Founder and President of Black Health Matters. "By participating in the Spot Her initiative, we hope to ensure Black women have educational resources to help advocate for themselves and the women in their lives." Spot Her Symbol and #SpotHerforEC Pledge To learn more about the Spot Her campaign and find helpful resources about endometrial cancer, please visit SpotHerforEC.com. About Endometrial Cancer About SHARE About FORCE For more information, visit FORCE's website at www.FacingOurRisk.org. About Black Health Matters About Eisai Inc. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
SOURCE Eisai Inc. |